Emerging Protein Biotherapeutics

Emerging Protein Biotherapeutics book cover

Emerging Protein Biotherapeutics

Author(s): Iqbal S. Grewal

  • Publisher: CRC Press
  • Publication Date: 26 Jun. 2009
  • Edition: 1st
  • Language: English
  • Print length: 368 pages
  • ISBN-10: 1420063200
  • ISBN-13: 9781420063202

Book Description

A Readily Applicable Framework for Novel Drug Design

It is only 20 years since the reach of genetic knowledge has allowed for the development of protein biotherapeutics, but in that time the pace has been fast. While the literature abounds, the field has lacked a comprehensive accounting of this progress. Emerging Protein Biotherapeutics consolidates current knowledge of key protein targets important in autoimmunity and cancers, exploring basic aspects and diverse clinical application.

Presents Strategies to Exploit Therapeutic Uses

In this volume, leading researchers cover many aspects of biology related to protein targets, ranging from the in vivo role in the disease process, to various strategies exploiting development of these targets for therapeutic use. Each chapter includes background, a discussion of clinical implications, an account of preclinical and clinical testing of various candidates, and a listing of key references.

This volume makes the study of protein biotherapeutics accessible at all levels of expertise. It offers an efficient and rational way to grasp the theoretical and experimental knowledge currently available while also providing a deeper understanding of disease processes. Most importantly, it presents a framework that can be readily employed by those looking to develop their own strategies in pursuit of new clinical applications.

Editorial Reviews

Review

Select Guide Rating

About the Author

Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.

View on Amazon

电子书代发PDF格式价格30我要求助
未经允许不得转载:Wow! eBook » Emerging Protein Biotherapeutics